Empliciti 300 mg
Elotuzumab is a malignancy drug utilized in the mix with lenalidomide and dexamethasone to treat patients with various myeloma who have gotten one to three earlier therapies2,3,4.
The dynamic substance in Empliciti, elotuzumab, is a monoclonal counter acting agent that actuates the body’s insusceptible cells to assault the numerous myeloma malignant growth cells. It does this by joining to a protein on the outside of the resistant cells called SLAMF7, making them act against the malignant growth cells and subsequently backing off the sickness. Elotuzumab likewise joins to SLAMF7 on the malignant growth cells, making them increasingly helpless against assault by the invulnerable cells.